Details for New Drug Application (NDA): 205376
✉ Email this page to a colleague
NDA 205376 describes BENDAMUSTINE HYDROCHLORIDE, which is a drug marketed by Accord Hlthcare, Apotex, Breckenridge, Dr Reddys, Eugia Pharma, Meitheal, Nang Kuang Pharm Co, Norvium Bioscience, Baxter Hlthcare Corp, and Hospira, and is included in eleven NDAs. It is available from seven suppliers. Additional details are available on the BENDAMUSTINE HYDROCHLORIDE profile page.
The generic ingredient in BENDAMUSTINE HYDROCHLORIDE is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.
The generic ingredient in BENDAMUSTINE HYDROCHLORIDE is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.
Summary for 205376
| Tradename: | BENDAMUSTINE HYDROCHLORIDE |
| Applicant: | Dr Reddys |
| Ingredient: | bendamustine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 205376
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;IV (INFUSION) | Strength | 25MG/VIAL | ||||
| Approval Date: | Dec 7, 2022 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;IV (INFUSION) | Strength | 100MG/VIAL | ||||
| Approval Date: | Dec 7, 2022 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
